Related Experiment Video
Updated: Jun 28, 2025

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
Identification of Inhibitors of the Disease-Associated Protein Phosphatase Scp1 Using Antibody Mimetic Molecules
Tamaki Kobayashi1, Kazuki Yamazaki1, Junki Shinada1
1Department of Chemistry, Faculty of Science, Niigata University, Niigata 950-2181, Japan.
Abstract:
Protein phosphorylation is a prevalent translational modification, and its dysregulation has been implicated in various diseases, including cancer. Despite its significance, there is a lack of specific inhibitors of the FCP/SCP-type Ser/Thr protein phosphatase Scp1, characterized by high specificity and affinity. In this study, we focused on adnectin, an antibody-mimetic protein, aiming to identify Scp1-specific binding molecules with a broad binding surface that target the substrate-recognition site of Scp1. Biopanning of Scp1 was performed using an adnectin-presenting phage library with a randomized FG loop. We succeeded in identifying FG-1Adn, which showed high affinity and specificity for Scp1. Ala scanning analysis of the Scp1-binding sequence in relation to the FG-1 peptide revealed that hydrophobic residues, including aromatic amino acids, play important roles in Scp1 recognition. Furthermore, FG-1Adn was found to co-localize with Scp1 in cells, especially on the plasma membrane. In addition, Western blotting analysis showed that FG-1Adn increased the phosphorylation level of the target protein of Scp1 in cells, indicating that FG-1Adn can inhibit the function of Scp1. These results suggest that FG-1Adn can be used as a specific inhibitor of Scp1.
Insights
Researchers developed FG-1Adn, a novel adnectin-based molecule, to specifically inhibit the Scp1 protein phosphatase. This discovery offers a potential therapeutic strategy for diseases linked to Scp1 dysregulation, such as cancer.
Area of Science:
- Molecular Biology
- Biochemistry
- Drug Discovery
Background:
- Protein phosphorylation is a key cellular process, and its dysregulation is linked to diseases like cancer.
- Specific inhibitors for the Ser/Thr protein phosphatase Scp1 are lacking, hindering research and therapeutic development.
Purpose of the Study:
- To identify high-affinity, specific binding molecules targeting the Scp1 phosphatase.
- To develop a novel inhibitor for Scp1 using adnectin-based technology.
Main Methods:
- Utilized adnectin-presenting phage display for biopanning against Scp1.
- Employed alanine scanning to analyze key residues for Scp1 recognition.
- Validated FG-1Adn's cellular localization and functional inhibition via Western blotting.
Main Results:
- Identified FG-1Adn, an adnectin molecule with high affinity and specificity for Scp1.
- Determined that hydrophobic residues are crucial for Scp1 recognition by FG-1Adn.
- Demonstrated that FG-1Adn co-localizes with Scp1 in cells and inhibits its phosphatase activity, increasing target protein phosphorylation.
Conclusions:
- FG-1Adn is a potent and specific inhibitor of the Scp1 protein phosphatase.
- This adnectin-based molecule represents a promising tool for studying Scp1 function and developing therapeutics for Scp1-related diseases.

